Science
PLL THERAPEUTICS
1 | EARLY DIAGNOSTIC
- – Early diagnostic with “immunologic profile” that identifies circulating antibodies in blood serum.
2 | TREATMENT Initiated
- – Treatment features groups of complementary compounds bound by PLL to increase half-life in the body and promotes the passage of the blood brain barrier for penetration into cells.
– Administered in 2x daily subcutaneous injections.
3 | TREATMENT Follow-up
- – Quarterly patient follow-up and disease tracking using the companion diagnostic.
The PLL approach: diagnostics
A proprietary diagnostic technology enables early diagnosis and disease tracking
-
Identification of the specific circulating antibodies for neurodegenerative diseases after indirect ELISA test and algorithm interpretation.
- The PNS diagnostic technology identifies circulating monoclonal antibodies and antigens (ROS molecules, pro-inflammatory elements) in blood serum and compares to markers present for the disease in question.
The PLL approach: PLL-01 therapy
… to define the best combination of compounds …
The PNS therapeutic approach is based on the following principle :
- Active molecules are linked to Poly-L-Lysine (PLL) which increases their half-life and thereby their systemic availability to exert their activity and/or cellular uptake.
- PLL was selected among other half-life enhancers as it may, by itself, have beneficial properties.
28 molecules with various propriety
-
Fatty acids 
Antioxidants 
Free radical scavengers 
Energy substrate 
Essential amino acids
Poly-L-Lysine coupling
Fully active final compound
More on PLL-01 therapy targets
A multi-target approach is needed for this multifactorial disease
PNS aims to counterbalance the multiple cellular metabolic defects of ALS and their consequences on motor-neurons, including :
- ROS (Reactive oxygen species)
- Glutamate
- Inflammatory mediators
- Amino acids
- Gut mucosal permeability
